Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Levy

Showing results (31-40 of 72) with videos related to

Pageof 8
Sort By:
Plos One|January 25, 2020
Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in FranceKevin Bowrin, Jean-Baptiste Briere, Laurent Fauchier, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 7, 2024
Cost-effectiveness analysis comparing single-pill combination of perindopril/amlodipine/indapamide to the free equivalent combination in patients with hypertension from an Italian national health system perspectivePierre Levy, Tobiasz Lemański, Catriona Crossan, et al.
Pharmacoeconomics - Open|August 22, 2023
Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE<sup>®</sup>) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical TrialLaurent Fauchier, Nicolas Lamblin, Jean Tardu, et al.
Journal of Clinical Medicine|March 11, 2020
Interstitial Lung Disease Associated with Lung Cancer: A Case-Control StudyQuentin Gibiot, Isabelle Monnet, Pierre Levy, et al.
Journal of Medical Economics|March 6, 2019
Migraine burden and costs in France: a nationwide claims database analysis of triptan usersAnne Donnet, Corinne Emery, Samia Aly, et al.
Current Medical Research and Opinion|July 23, 2019
Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin-K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillationJean-Baptiste Briere, Olivia Wu, Kevin Bowrin, et al.
Cardiovascular Research|December 7, 2019
Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery diseaseMartin R Cowie, André Lamy, Pierre Levy, et al.
Journal of Market Access & Health Policy|February 19, 2019
Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillationCraig I Coleman, Jean-Baptiste Briere, Laurent Fauchier, et al.
Histopathology|March 14, 2014
Prognostic relevance of histological variants in nonspecific interstitial pneumoniaMarianne Kambouchner, Pierre Levy, Andrew G Nicholson, et al.
Journal of Sleep Research|April 7, 2021
Sleep scoring based on video-electroencephalography monitoring in an Epileptology Unit: Comparison with polysomnographyVi-Huong Nguyen-Michel, Bastien Herlin, Ana Gales, et al.
Pageof 8

Showing results (31-40 of 72) with videos related to

Sort By:
Pageof 8
Plos One|January 25, 2020
Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in FranceKevin Bowrin, Jean-Baptiste Briere, Laurent Fauchier, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 7, 2024
Cost-effectiveness analysis comparing single-pill combination of perindopril/amlodipine/indapamide to the free equivalent combination in patients with hypertension from an Italian national health system perspectivePierre Levy, Tobiasz Lemański, Catriona Crossan, et al.
Pharmacoeconomics - Open|August 22, 2023
Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE<sup>®</sup>) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical TrialLaurent Fauchier, Nicolas Lamblin, Jean Tardu, et al.
Journal of Clinical Medicine|March 11, 2020
Interstitial Lung Disease Associated with Lung Cancer: A Case-Control StudyQuentin Gibiot, Isabelle Monnet, Pierre Levy, et al.
Journal of Medical Economics|March 6, 2019
Migraine burden and costs in France: a nationwide claims database analysis of triptan usersAnne Donnet, Corinne Emery, Samia Aly, et al.
Current Medical Research and Opinion|July 23, 2019
Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin-K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillationJean-Baptiste Briere, Olivia Wu, Kevin Bowrin, et al.
Cardiovascular Research|December 7, 2019
Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery diseaseMartin R Cowie, André Lamy, Pierre Levy, et al.
Journal of Market Access & Health Policy|February 19, 2019
Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillationCraig I Coleman, Jean-Baptiste Briere, Laurent Fauchier, et al.
Histopathology|March 14, 2014
Prognostic relevance of histological variants in nonspecific interstitial pneumoniaMarianne Kambouchner, Pierre Levy, Andrew G Nicholson, et al.
Journal of Sleep Research|April 7, 2021
Sleep scoring based on video-electroencephalography monitoring in an Epileptology Unit: Comparison with polysomnographyVi-Huong Nguyen-Michel, Bastien Herlin, Ana Gales, et al.
Pageof 8